Wayne Kuznar
Authored Items
By Wayne Kuznar
November 2022 – Lung Cancer
Many biologic markers (biomarkers) are known to drive cancer and its progression, allowing scientists to develop new medications to target those biomarkers and increase survival for patients with lung cancer. Read More ›
By Wayne Kuznar
April 2022 Vol 8 No 2
This article offers an overview of the unique challenges affecting the LGBTQ community when faced with a cancer diagnosis, from delayed screenings to isolation and lack of access to resources and best care. Read More ›
By Wayne Kuznar
February 2022 Vol 8 No 1
HPV is a major cause of throat cancer and is rising in the United States. Learn about the symptoms of throat cancer, treatment options, and the benefits of a shorter course of treatment for certain patients. Read More ›
By Wayne Kuznar
November 2021 – Lung Cancer
For the first time, the use of immunotherapy after surgical removal of the tumor and chemotherapy has shown benefits in patients with early-stage non–small-cell lung cancer (NSCLC) and PD-L1 expression, a biomarker found in some patients with NSCLC. Read More ›
By Wayne Kuznar
June 2021 Vol 7 No 3
HPV infection is the most common sexually transmitted disease and the cause of several types of cancer, including anal cancer. Several experts explain the effectiveness of the HPV vaccine in preventing these cancers, something that we should all be aware of. Read More ›
By Wayne Kuznar
ASCO 2020 Highlights
The follow-up results of more than 5 years of the multicenter phase 3 SOLO2 clinical trial of women with ovarian cancer were presented at the 2020 ASCO annual meeting, showing improved survival with the use of Lynparza (olaparib) compared with placebo. Read More ›
By Wayne Kuznar
ASCO 2020 Highlights
Several immunotherapies known as immune checkpoint inhibitors are available today for patients with melanoma, as well as targeted therapies for patients with a BRAF or MEK gene mutation, but there are no effective treatments approved for patients with metastatic (spreading) or nonresectable (cannot be removed by surgery) melanoma whose disease progressed (got worse) after using an immune checkpoint inhibitor, or a BRAF or MEK inhibitor for those with gene mutations. Read More ›
By Wayne Kuznar
ASCO 2020 Highlights
A total of 80% of patients with relapsed (coming back) or refractory (not responding to therapy) slow-growing (indolent) non-Hodgkin lymphoma (NHL)—including patients with follicular lymphoma or marginal-zone lymphoma (MZL)—achieved a complete response (no sign of cancer) to Yescarta (axicabtagene ciloleucel), an anti-CD19 CAR T-cell therapy. Read More ›
By Wayne Kuznar
ASCO 2020 Highlights
Treatment with the targeted drug Tagrisso (osimertinib) as an adjuvant therapy (used in addition to primary therapy, such as surgery or chemotherapy) significantly reduces disease recurrence in patients with localized non–small-cell lung cancer (NSCLC) and an EGFR gene mutation (alteration). Read More ›
By Wayne Kuznar
ASCO 2020 Highlights
The use of first-line immunotherapy combination with Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) continues to show robust, long-term benefit in patients with microsatellite instability high (MSI-H) or with mismatch repair-deficient (dMMR) metastatic (spreading) colorectal cancer, according to new study results presented at the 2020 ASCO annual meeting. Read More ›
By Wayne Kuznar
May 2020 – Biomarkers & Genetic Testing
Genetic testing, genomic testing, molecular profiling—how can you make sense of these terms to ensure you receive the best test and best treatment in this era of targeted therapies? A group of experts and patient advocates provide answers to these questions. Read More ›
By Wayne Kuznar
May 2020 – Biomarkers & Genetic Testing
New treatments are becoming available for patients with cholangiocarcinoma (bile duct cancer). Testing for specific biomarkers is crucial to ensure each patient receives the best available treatment for any associated biomarker. Read More ›
By Wayne Kuznar
June 2018 – Cancer Immunotherapy
The National Comprehensive Cancer Care Network and the American Society of Clinical Oncology recently issued the first set of recommendations for the management of immunotherapy side-effects. Read More ›
By Wayne Kuznar
June 2017 – Cancer Immunotherapy
Immunotherapy is all the rage today, but like any other treatment, it comes with side effects. Learn how to recognize and manage some of the common side effects. Read More ›